Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107715 | 0.90 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1107643 | 0.90 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL2668931 | 0.85 | GCK (0.61) | GCKKCNH2CYP2C9 | |
| SCHEMBL3608759 | 0.75 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL13255211 | 0.74 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL9891681 | 0.74 | GCK (0.65) | GCKKCNH2 | |
| SCHEMBL1107597 | 0.74 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL9071286 | 0.74 | GCK (0.74) | GCKKCNH2CYP2C9 | |
| SCHEMBL3608166 | 0.73 | GCK (1.00) | GCK | |
| SCHEMBL9891682 | 0.73 | GCK (0.66) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885KCNH2 634/4885CYP2C9 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.